NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NRXP

NRX Pharmaceuticals Inc

Jul 11 • 04:00PM ET

3.21

Dollar change -0.06
Percentage change -1.83	%

Healthcare • Biotechnology • USA • NASD

Peers: LGND ARDX FGEN DVAX BCRX GERN ALDX ANVS APVO CRBP

| Held by: PSIL VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.01	Insider Own	17.08%	Shs Outstand	17.12M	Perf Week	-5.03%
Market Cap	62.61M	Forward P/E	4.60	EPS next Y	0.70	Insider Trans	0.00%	Shs Float	16.17M	Perf Month	-12.05%
Enterprise Value	65.46M	PEG	-	EPS next Q	-0.20	Inst Own	11.59%	Short Float	5.58%	Perf Quarter	80.34%
Income	-24.11M	P/S	-	EPS this Y	94.51%	Inst Trans	1.21%	Short Ratio	3.46	Perf Half Y	-31.12%
Sales	0.00M	P/B	-	EPS next Y	637.86%	ROA	-423.80%	Short Interest	0.90M	Perf YTD	45.91%
Book/sh	-1.47	P/C	11.28	EPS next 5Y	-	ROE	-	52W High	6.01 -46.59%	Perf Year	49.30%
Cash/sh	0.28	P/FCF	-	EPS past 3/5Y	68.34% -	ROIC	-	52W Low	1.10 191.82%	Perf 3Y	-42.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.36% 6.59%	Perf 5Y	-96.95%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	36.97%	Oper. Margin	-	ATR (14)	0.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.22	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.09	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.22	EPS Q/Q	54.45%	SMA20	-3.28%	Beta	1.61	Target Price	31.67
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	12.12%	Rel Volume	0.65	Prev Close	3.27
Employees	-	LT Debt/Eq	-	Earnings	May 15 AMC	SMA200	43.64%	Avg Volume	260.57K	Price	3.21
IPO	Dec 04, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-20.01% -	Trades		Volume	169,603	Change	-1.83%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-25	Initiated	BTIG Research	Buy	$18

Jul-08-25 03:30PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic (NewMediaWire)
Jun-30-25 02:30PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner's National Priority Voucher for IV Ketamine NRX-100 (NewMediaWire)
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
Jun-26-25 03:00PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic (NewMediaWire) +7.03%
08:03AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics (PR Newswire)
08:03AM	Loading…
Jun-23-25 08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100) (PR Newswire)
Jun-16-25 02:30PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners (NewMediaWire)
08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners (PR Newswire)
Jun-12-25 08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference (PR Newswire)
Jun-06-25 02:30PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network (NewMediaWire) +11.22%
Jun-05-25 02:39PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine (NewMediaWire)
08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine (PR Newswire)
May-28-25 03:30PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval (NewMediaWire)
May-27-25 07:56PM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network (Insider Monkey)
02:30PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition (NewMediaWire)
12:57PM	Loading…
May-21-25 12:57PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21 (NewMediaWire) -5.40%
08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida (PR Newswire)
May-20-25 01:00PM	IBN Coverage: Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform (NewMediaWire) +13.93%
May-16-25 01:14PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup (NewMediaWire)
03:13AM	NRX Pharmaceuticals Inc (NRXP) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
May-15-25 04:03PM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) +5.73%
02:00PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE's Strategic Kadima Agreement (NewMediaWire)
10:15AM	HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions (PR Newswire)
May-13-25 02:00PM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute (NewMediaWire) +10.10%
08:03AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics (PR Newswire)
May-12-25 08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 (PR Newswire)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
May-06-25 09:30AM	IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation (NewMediaWire) -5.42%
08:03AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025 (PR Newswire)
May-05-25 08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine (PR Newswire)
08:46AM	Loading…
Apr-30-25 08:46AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression (PR Newswire)
Apr-21-25 08:01AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025 (PR Newswire)
Apr-03-25 08:03AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE (PR Newswire) -6.97%
Mar-31-25 08:02AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics (PR Newswire)
Mar-27-25 09:55AM	Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-24-25 08:02AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics (PR Newswire)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-18-25 03:01AM	NRX Pharmaceuticals Inc (NRXP) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com) +7.32%
Mar-17-25 08:02AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire) -12.77%
Mar-12-25 08:01AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025 (PR Newswire)
Mar-01-25 10:29AM	NRx Pharmaceuticals, Inc. (NRXP): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-06-25 08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 (PR Newswire) +11.97%
Feb-03-25 08:59AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor (PR Newswire) -7.28%
Jan-28-25 08:05AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition (PR Newswire) +24.56%
08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt (PR Newswire)
Jan-21-25 08:02AM	NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement (PR Newswire) -11.97%
Jan-15-25 08:02AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc. (PR Newswire) -11.96%
Jan-14-25 08:03AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel (PR Newswire)
Jan-13-25 08:04AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market (PR Newswire)
Jan-10-25 08:04AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago Club (PR Newswire) +28.99%
Jan-08-25 10:20AM	Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region (GlobeNewswire) -19.31%
Jan-07-25 08:07AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco (PR Newswire) +32.76%
Jan-06-25 10:16AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations (PR Newswire) +30.48%
08:03AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics (PR Newswire)
Jan-03-25 08:03AM	HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025 (PR Newswire) -10.03%
Jan-02-25 08:03AM	Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics (PR Newswire) +35.91%
Dec-30-24 08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression (PR Newswire)
Nov-26-24 08:03AM	NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024 (PR Newswire)
Nov-25-24 08:03AM	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled 'Quality Assurance of Depression Ratings in Psychiatric Clinical Trials' (PR Newswire)
Nov-19-24 02:03AM	NRX Pharmaceuticals Inc (NRXP) Q3 2024 Earnings Call Highlights: Significant Reduction in ... (GuruFocus.com) -5.77%
Nov-18-24 04:05PM	NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer (PR Newswire) +9.24%
Nov-14-24 04:05PM	NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update (PR Newswire) -7.20%
Nov-13-24 08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 (PR Newswire)
Nov-07-24 04:06PM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024 (PR Newswire)
Oct-31-24 07:00AM	NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule (GlobeNewswire)
Oct-30-24 07:47AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics (PR Newswire) +12.60%
Oct-23-24 08:30AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 (GlobeNewswire)
Oct-12-24 05:18PM	NRx Pharmaceuticals Leadership Shift and Strategic Governance Decisions (TipRanks)
Oct-03-24 06:55AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic (PR Newswire)
Sep-30-24 07:00AM	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine) (PR Newswire)
Sep-11-24 07:55AM	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com (PR Newswire)
Sep-03-24 07:55AM	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 (PR Newswire) -12.03%
Aug-26-24 07:55AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics (PR Newswire) -9.13%
Aug-14-24 04:01PM	NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update (PR Newswire) -6.45%
Aug-13-24 04:01PM	NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024 (PR Newswire) -7.31%
07:30AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds (PR Newswire)
Jul-29-24 08:35AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine) (PR Newswire)
08:30AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals (Nasdaq:NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff (PR Newswire)
Jul-01-24 08:07AM	NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter (PR Newswire) +5.74%
Jun-28-24 08:07AM	NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing (PR Newswire) -6.87%
Jun-20-24 08:30AM	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 (PR Newswire)
Jun-18-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors (PR Newswire)
Jun-10-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter (PR Newswire)
May-28-24 08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression (PR Newswire)
May-14-24 08:57PM	NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace) +6.35%
04:01PM	NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-08-24 09:55AM	NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update (ACCESSWIRE)
08:30AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024 (PR Newswire)
May-07-24 04:01PM	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024 (PR Newswire) -8.17%
May-06-24 08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression (PR Newswire) +45.71%
Apr-30-24 08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression (PR Newswire) -27.32%
Apr-18-24 08:56AM	Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today? (InvestorPlace) -27.75%
08:32AM	NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement (PR Newswire)
08:30AM	NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock (PR Newswire)
Apr-17-24 04:45PM	NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire)
08:30AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections (PR Newswire)
Apr-15-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) (PR Newswire)
Apr-08-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression (PR Newswire)
Apr-04-24 12:00PM	NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +9.70%
Apr-02-24 10:33AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcript (Insider Monkey)

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Javitt Jonathan C	Chairman and Chief Scientist	Dec 17 '24	Buy	1.17	40,000	46,800	84,634	Dec 18 08:27 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRXP

NRX Pharmaceuticals Inc

Upgrade your FINVIZ experience